Stock Events

Stock Events

PDS Biotechnology 

$0.2185
59
+$0.01+4.6% Friday 20:00
-$0.00-0.05%Friday 23:52After hours

Statistics

Day High
0.2173
Day Low
0.2146
52W High
1.55
52W Low
0.195
Volume
2,344
Avg. Volume
-
Mkt Cap
12.23M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.28
-0.22
-0.17
-0.12
Expected EPS
-0.12
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-36.84MNet Income

Analyst Ratings

7.00Average Price Target
The highest estimate is 7.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PDSB. It's not an investment recommendation.
NVIDIA
6
NVDA
Alphabet
6
GOOGL
Coca-Cola
6
KO
Pfizer
6
PFE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation operates in the same biopharmaceutical space, focusing on the discovery, development, and commercialization of proprietary therapeutics, including cancer immunotherapies that compete with PDS Biotechnology's pipeline.
Merck
MRK
Mkt Cap335.14B
Merck & Co., Inc. is a global healthcare company that offers immunotherapy products, including cancer vaccines and therapies that could be seen as alternatives or competitors to PDS Biotechnology's products.
BioNTech
BNTX
Mkt Cap23.38B
BioNTech SE works on patient-specific immunotherapies for cancer and other diseases, using a wide range of therapeutic modalities that could compete with PDS Biotechnology's versatile platform.
Novavax
NVAX
Mkt Cap1.33B
Novavax, Inc. is involved in the development of vaccines for infectious diseases, which could compete with PDS Biotechnology's infectious disease vaccine candidates.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that develops and markets therapies in areas where PDS Biotechnology is also active, particularly in oncology and infectious diseases.
AMGEN
AMGN
Mkt Cap224.63B
Amgen Inc. is a biotechnology pioneer that develops and delivers innovative human therapeutics, including immunotherapies for cancer, which competes with PDS Biotechnology's product pipeline.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson engages in the research and development, manufacture, and sale of a broad range of products in the healthcare field, including immunotherapies and vaccines that could compete with PDS Biotechnology's offerings.

About

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
Show more...
CEO
Frank K. Bedu-Addo
Employees
21
Country
United States
ISIN
US70465T1079
WKN
000A2PF3F

Listings

STU
DE
EU6.STU
MU
DE
EU6.MU
XNAS
US
PDSB
F
DE
EU6.F

0 Comments

Share your thoughts

FAQ

What is PDS Biotechnology stock price today?▼
The current price of PDSB is $0.22 USD — it has increased by +4.6% in the past 24 hours. Watch PDS Biotechnology stock price performance more closely on the chart.
What is PDS Biotechnology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange PDS Biotechnology stocks are traded under the ticker PDSB.
Is PDS Biotechnology stock price growing?▼
PDSB stock has fallen by -5.25% compared to the previous week, the month change is a -68.81% fall, over the last year PDS Biotechnology has showed a -81.64% decrease.
What is PDS Biotechnology market cap?▼
Today PDS Biotechnology has the market capitalization of 12.23M
When is the next PDS Biotechnology earnings date?▼
PDS Biotechnology is going to release the next earnings report on November 12, 2026.
What were PDS Biotechnology earnings last quarter?▼
PDSB earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.13 USD resulting in a -38.46% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PDS Biotechnology revenue for the last year?▼
PDS Biotechnology revenue for the last year amounts to 0 USD.
What is PDS Biotechnology net income for the last year?▼
PDSB net income for the last year is -36.84M USD.
How many employees does PDS Biotechnology have?▼
As of August 23, 2026, the company has 21 employees.
In which sector is PDS Biotechnology located?▼
PDS Biotechnology operates in the Health & Wellness sector.
When did PDS Biotechnology complete a stock split?▼
The last stock split for PDS Biotechnology was on March 18, 2019 with a ratio of 1:20.
Where is PDS Biotechnology headquartered?▼
PDS Biotechnology is headquartered in PRINCETON, United States.